

David Owens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7660951/publications.pdf>

Version: 2024-02-01

77
papers

5,026
citations

136885

32
h-index

88593

70
g-index

77
all docs

77
docs citations

77
times ranked

4948
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of a New Neural Network Classifier for Diabetic Retinopathy. Journal of Diabetes Science and Technology, 2022, 16, 1401-1409.	1.3	5
2	Insulin Centennial: Milestones influencing the development of insulin preparations since 1922. Diabetes, Obesity and Metabolism, 2022, 24, 27-42.	2.2	8
3	One-hundred year evolution of prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. Metabolism: Clinical and Experimental, 2022, 126, 154935.	1.5	7
4	Below Which Threshold of Glycemic Variability Is There a Minimal Risk of Hypoglycemia in People with Type 2 Diabetes?. Diabetes Technology and Therapeutics, 2022, 24, 453-454.	2.4	4
5	Risk factors for having diabetic retinopathy at first screening in persons with type 1 diabetes diagnosed under 18 years of age. Eye, 2021, 35, 2840-2847.	1.1	7
6	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia, 2021, 64, 275-287.	2.9	140
7	Characteristics of repeat non-attenders at Diabetes Eye Screening Wales, a national community-based diabetes-related retinopathy screening service, during 2003-2018. Diabetic Medicine, 2021, 38, e14536.	1.2	8
8	A retrospective epidemiological study of Type 1 Diabetes Mellitus in Wales, UK between 2008 and 2018. International Journal of Population Data Science, 2021, 6, 1387.	0.1	3
9	Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the "Gordian Knot?". Diabetes and Metabolism, 2021, 47, 101225.	1.4	34
10	Si l'ère des insulines semi-synthétiques et biosynthétiques nous attendait. Medecine Des Maladies Metaboliques, 2021, 15, 3S32-3S52.	0.1	1
11	Glycaemic variabilities: Key questions in pursuit of clarity. Diabetes and Metabolism, 2021, 47, 101283.	1.4	9
12	Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100%U/mL. Diabetes, Obesity and Metabolism, 2020, 22, 315-323.	2.2	13
13	Respective Contributions of Glycemic Variability and Mean Daily Glucose as Predictors of Hypoglycemia in Type 1 Diabetes: Are They Equivalent?. Diabetes Care, 2020, 43, 821-827.	4.3	41
14	Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening. European Journal of Health Economics, 2020, 21, 993-1002.	1.4	11
15	Review of methods for detecting glycemic disorders. Diabetes Research and Clinical Practice, 2020, 165, 108233.	1.1	108
16	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes, Obesity and Metabolism, 2020, 22, 743-754.	2.2	50
17	The burden of type 2 diabetes in Europe: Current and future aspects of insulin treatment from patient and healthcare spending perspectives. Diabetes Research and Clinical Practice, 2020, 161, 108053.	1.1	33
18	The impact of structured self-monitoring of blood glucose on glycaemic variability in non-insulin treated type 2 diabetes: The SMBG study, a 12-month randomised controlled trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 101-106.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Glycaemic variability in diabetes: clinical and therapeutic implications. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 221-230.	5.5	363
20	Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non-insulin treated Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial. <i>Diabetic Medicine</i> , 2019, 36, 578-590.	1.2	22
21	IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107840.	1.1	202
22	Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0%. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 321-329.	2.2	15
23	Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, Tj ETQq1 1 0.784314 rgBT / <i>Overlock</i> 10 and <i>Metabolism</i> , 2019, 45, 330-340.	1.4	14
24	Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naïve individuals with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2894-2898.	2.2	3
25	Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. <i>Diabetes Research and Clinical Practice</i> , 2017, 124, 57-65.	1.1	33
26	Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. <i>Cardiovascular Diabetology</i> , 2017, 16, 6.	2.7	107
27	Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. <i>BMC Endocrine Disorders</i> , 2017, 17, 4.	0.9	12
28	Future challenges and therapeutic opportunities in type 2 diabetes: changing the paradigm of current therapy. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1339-1352.	2.2	33
29	A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1645-1654.	2.2	24
30	Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treatment target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1546-1554.	2.2	8
31	Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes. <i>Diabetes Care</i> , 2017, 40, 832-838.	4.3	262
32	Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 µg intravitreal implant in people with diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2017, 33, 5-17.	0.9	27
33	Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes. <i>Current Medical Research and Opinion</i> , 2017, 33, 19-31.	0.9	14
34	Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. <i>Current Medical Research and Opinion</i> , 2017, 33, 33-43.	0.9	14
35	Retrospective analysis of newly recorded certifications of visual impairment due to diabetic retinopathy in Wales during 2007-2015. <i>BMJ Open</i> , 2017, 7, e015024.	0.8	27
36	Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy. <i>European Endocrinology</i> , 2017, 13, 21.	0.8	8

#	ARTICLE	IF	CITATIONS
37	When should screening for diabetic retinopathy begin for children with type 1 diabetes?. Expert Review of Endocrinology and Metabolism, 2016, 11, 97-102.	1.2	4
38	Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 977-987.	1.5	32
39	Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials. Journal of Diabetes and Its Complications, 2016, 30, 1622-1630.	1.2	6
40	Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. Diabetes Therapy, 2016, 7, 187-201.	1.2	29
41	Diabetic Retinopathy in Newly Diagnosed Subjects With Type 2 Diabetes Mellitus: Contribution of β^2 -Cell Function. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 572-580.	1.8	15
42	Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. British Journal of Ophthalmology, 2015, 99, 64-68.	2.1	158
43	Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: A pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials. Diabetes Research and Clinical Practice, 2014, 106, 264-274.	1.1	32
44	Basal insulin analogues in the management of diabetes mellitus: what progress have we made?. Diabetes/Metabolism Research and Reviews, 2014, 30, 104-119.	1.7	83
45	Does bariatric surgery adversely impact on diabetic retinopathy in persons with morbid obesity and type 2 diabetes? A pilot study. Journal of Diabetes and Its Complications, 2014, 28, 191-195.	1.2	47
46	New Meta-Analysis of Patient-Level Data on Efficacy And Hypoglycaemia with Insulin Glargine or Nph Insulin in Type 2 Diabetes Mellitus (T2DM) According to Concomitant Oral Therapy. Value in Health, 2014, 17, A335.	0.1	1
47	Stepwise intensification of insulin therapy in Type 2 diabetes management—exploring the concept of the basal-plus approach in clinical practice. Diabetic Medicine, 2013, 30, 276-288.	1.2	40
48	Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. Diabetes and Metabolism, 2013, 39, 485-496.	1.4	66
49	Clinical Evidence for the Earlier Initiation of Insulin Therapy in Type 2 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 776-785.	2.4	72
50	Magnitude of the Dawn Phenomenon and Its Impact on the Overall Glucose Exposure in Type 2 Diabetes. Diabetes Care, 2013, 36, 4057-4062.	4.3	87
51	Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ: British Medical Journal, 2012, 344, e874-e874.	2.4	114
52	Glargine and Cancer: Can We Now Suggest Closure?. Diabetes Care, 2012, 35, 2426-2428.	4.3	10
53	Optimizing treatment strategies with insulin glargine in Type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2012, 7, 377-393.	1.2	4
54	Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet, The, 2012, 379, 2262-2269.	6.3	100

#	ARTICLE	IF	CITATIONS
55	Response Letter to D. Singh&Franco et al.. Diabetes, Obesity and Metabolism, 2012, 14, 1054-1055.	2.2	0
56	The Emergence of Biosimilar Insulin Preparations&A Cause for Concern?. Diabetes Technology and Therapeutics, 2012, 14, 989-996.	2.4	60
57	Insulin Preparations with Prolonged Effect. Diabetes Technology and Therapeutics, 2011, 13, S-5-S-14.	2.4	103
58	The Contribution of Glucose Variability to Asymptomatic Hypoglycemia in Persons with Type 2 Diabetes. Diabetes Technology and Therapeutics, 2011, 13, 813-818.	2.4	147
59	Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes, Obesity and Metabolism, 2011, 13, 251-257.	2.2	30
60	Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month &proof-of-concept' study. Diabetes, Obesity and Metabolism, 2011, 13, 1020-1027.	2.2	83
61	Regulation of oxidative stress by glycaemic control: evidence for an independent inhibitory effect of insulin therapy. Diabetologia, 2010, 53, 562-571.	2.9	126
62	A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. Diabetes Research and Clinical Practice, 2008, 79, 269-275.	1.1	37
63	Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet, The, 2008, 371, 1073-1084.	6.3	295
64	Beyond the Era of NPH Insulin&Long-Acting Insulin Analogs: Chemistry, Comparative Pharmacology, and Clinical Application. Diabetes Technology and Therapeutics, 2008, 10, 333-349.	2.4	78
65	The Loss of Postprandial Glycemic Control Precedes Stepwise Deterioration of Fasting With Worsening Diabetes. Diabetes Care, 2007, 30, 263-269.	4.3	419
66	When basal insulin therapy in type 2 diabetes mellitus is not enough&what next?. Diabetes/Metabolism Research and Reviews, 2007, 23, 257-264.	1.7	102
67	Insulin glargine: commentary on the duration of action and lower risk of nocturnal hypoglycaemia in patients with diabetes. Expert Opinion on Pharmacotherapy, 2004, 5, 1-3.	0.9	1
68	The quest for physiologic insulin replacement. Postgraduate Medicine, 2004, 116, 4-12.	0.9	0
69	Alternative routes of insulin delivery. Diabetic Medicine, 2003, 20, 886-898.	1.2	307
70	Thiazolidinediones. Clinical Drug Investigation, 2002, 22, 485-505.	1.1	20
71	Insulin sensitivity in Type 2 diabetes: univariate and multivariate techniques to derive estimates of insulin sensitivity from the insulin modified intravenous glucose tolerance test (FSIGT). Computer Methods and Programs in Biomedicine, 2002, 68, 161-176.	2.6	6
72	New horizons &alternative routes for insulin therapy. Nature Reviews Drug Discovery, 2002, 1, 529-540.	21.5	182

#	ARTICLE	IF	CITATIONS
73	Insulin glargine (Lantus). <i>International Journal of Clinical Practice</i> , 2002, 56, 460-6.	0.8	21
74	Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. <i>Diabetes, Nutrition & Metabolism</i> , 2002, 15, 19-27.	0.4	6
75	Insulins today and beyond. <i>Lancet, The</i> , 2001, 358, 739-746.	6.3	353
76	Repaglinide: prandial glucose regulation in clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2000, 2, S43-S48.	2.2	8
77	Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. <i>Diabetes Care</i> , 2000, 23, 518-523.	4.3	62